AcelRx Pharmaceuticals, Inc. (ACRX)

NASDAQ: ACRX · IEX Real-Time Price · USD
0.214
+0.007 (3.47%)
At close: Sep 27, 2022 4:00 PM
0.210
-0.004 (-2.05%)
After-hours: Sep 27, 2022 4:05 PM EDT
3.47%
Market Cap 31.59M
Revenue (ttm) 2.88M
Net Income (ttm) 45.70M
Shares Out 147.33M
EPS (ttm) 0.30
PE Ratio 0.71
Forward PE 1.06
Dividend n/a
Ex-Dividend Date n/a
Volume 685,032
Open 0.210
Previous Close 0.207
Day's Range 0.208 - 0.225
52-Week Range 0.160 - 1.080
Beta 0.27
Analysts Buy
Price Target 4.08 (+1,803.0%)
Earnings Date Nov 14, 2022

About ACRX

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 ... [Read more...]

Industry Pharmaceuticals
IPO Date Feb 14, 2011
CEO Vincent Angotti
Employees 43
Stock Exchange NASDAQ
Ticker Symbol ACRX
Full Company Profile

Financial Performance

In 2021, ACRX's revenue was $2.82 million, a decrease of -47.97% compared to the previous year's $5.42 million. Losses were -$35.10 million, -13.08% less than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for ACRX stock is "Buy." The 12-month stock price forecast is 4.08, which is an increase of 1,802.99% from the latest price.

Price Target
$4.08
(1,802.99% upside)
Analyst Consensus: Buy
Stock Forecasts

News

AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference

HAYWARD, Calif., Sept. 6, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative ...

2 weeks ago - PRNewsWire

AcelRx Pharmaceuticals Announces a Second Abstract on DSUVIA® Accepted for Presentation at the ANESTHESIOLOGY® 2022 A...

Experts from the Uniformed Services University of the Health Sciences conclude that future battlefield medicine efforts should focus on newer analgesics like DSUVIA® across military settings and establi...

1 month ago - PRNewsWire

AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Misses Revenue Estimates

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 0% and 5%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

AcelRx Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Advanced Niyad™ supply chain development with a focus on obtaining an Emergency Use Authorization in 2023 $0.6 million net revenue in Q2 2022; fifth consecutive quarter of commercial (ex-DoD) sales volu...

1 month ago - PRNewsWire

Why Is AcelRx (ACRX) Stock up 26% Today?

Source: Shutterstock AcelRx Pharmaceuticals (NASDAQ: ACRX ) stock is seeing major gains on Thursday after announcing a presentation for the upcoming Plastic Surgery: The Meeting 2022. That meeting is se...

1 month ago - InvestorPlace

AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at Plastic Surgery: The Meeting 2022

HAYWARD, Calif. , Aug. 11, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative t...

1 month ago - PRNewsWire

AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting

HAYWARD, Calif. , Aug. 10, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative t...

1 month ago - PRNewsWire

AcelRx to Host Second Quarter 2022 Financial Results Call and Webcast on August 11, 2022

HAYWARD, Calif. , July 28, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release second quarter financial results aft...

1 month ago - PRNewsWire

AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Global Investment Conference

HAYWARD, Calif., May 20, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative t...

4 months ago - PRNewsWire

Why AcelRx Pharma Shares Are Trading Higher Today?

The FDA has recently modified the AcelRx Pharmaceuticals Inc's (NASDAQ: ACRX) Dsuvia Risk Evaluation and Mitigation Strategies (REMS) requirements for healthcare setting audits.  The Dsuvia REMS program...

4 months ago - Benzinga

AcelRx Pharmaceuticals Provides Update on Reduced FDA REMS Requirements Related to DSUVIA®

HAYWARD, Calif., May 19, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative t...

4 months ago - PRNewsWire

AcelRx Pharmaceuticals (ACRX) Reports Q1 Loss, Lags Revenue Estimates

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 0% and 11.60%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

AcelRx Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

Realigning cost structure from a focus on commercialization to a focus on development to advance late-stage pipeline; expected to result in annual savings of $9 million Completed acquisition of Lowell T...

4 months ago - PRNewsWire

AcelRx Pharmaceuticals Announces Publication of Results from an Investigator-Initiated Trial on Sufentanil Sublingual...

Study found that SST lowered the opioid dose required by patients in the post-anesthesia care unit (PACU) by more than five-fold compared to standard intravenous opioid administration HAYWARD, Calif. , ...

4 months ago - PRNewsWire

AcelRx to Host First Quarter 2022 Financial Results Call and Webcast on May 16, 2022

HAYWARD, Calif. , May 9, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release first quarter financial results before...

4 months ago - PRNewsWire

Minimal Side Effects and Short Recovery Time Reported for DSUVIA®-Treated Patients: Plastic Surgery Podium Presentati...

HAYWARD, Calif. , April 25, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovativ...

5 months ago - PRNewsWire

AcelRx Pharmaceuticals Announces Upcoming Podium Presentation on Use of DSUVIA® for Plastic Surgery Procedures at The...

HAYWARD, Calif. , April 21, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovativ...

5 months ago - PRNewsWire

AcelRx Pharmaceuticals Announces Publication of Results from a Clinical Study Assessing Use of Sufentanil Sublingual ...

Study results show higher rates of successful procedure completion and higher patient and clinician satisfaction scores compared to topical local anesthesia alone HAYWARD, Calif. , March 31, 2022 /PRNew...

5 months ago - PRNewsWire

AcelRx Pharmaceuticals Announces Publication of Clinical Data Finding Potential Benefits of Nafamostat Compared to Re...

Study results demonstrate that nafamostat had similar efficacy as citrate, while providing lower toxicity and lower costs to the hospital over standard citrate anticoagulation. HAYWARD, Calif.

5 months ago - PRNewsWire

AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Misses Revenue Estimates

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 0% and 99.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

HAYWARD, Calif., March 10, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative t...

6 months ago - PRNewsWire

AcelRx to Host Fourth Quarter and Full Year 2021 Financial Results Call and Webcast on March 10, 2022

HAYWARD, Calif., March 3, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release fourth quarter financial results afte...

6 months ago - PRNewsWire

AcelRx Pharmaceuticals Announces Publication of Clinical Data on the Use of Sufentanil Sublingual Tablet during Awake...

HAYWARD, Calif., Feb. 1, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for...

7 months ago - PRNewsWire

AcelRx Pharmaceuticals Announces Publication of an Article Highlighting the Utility of the Sufentanil Sublingual Tabl...

HAYWARD, Calif., Jan. 27, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies fo...

8 months ago - PRNewsWire

AcelRx Pharmaceuticals Announces Publication of an Editorial by an Internationally Recognized Leader in Opioid-Sparin...

HAYWARD, Calif., Jan. 12, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies fo...

8 months ago - PRNewsWire